Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00782535 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: CHF 4226 pMDI
DRUG: CHF 4226 pMDI
DRUG: Placebo

Sponsor

Chiesi Farmaceutici S.p.A.